Pharmaceuticals Analysts discuss the anticipated adoption and use of Biogen (BIIB) and Sage Therapeutics’ (SAGE) Zuranolone, once it receives FDA approval, on an Analyst/Industry conference call to be held on July 7.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
- Alcyone Therapeutics gets FDA IDE to initiate study of ThecaFlex DRx System
- CMS update ‘incremental positive’ for Biogen, says William Blair
- Sage Therapeutics price target raised to $66 from $61 at BofA
- Biogen Announces Changes to Its Board of Directors